Data / Drug companies / Hospira, Inc.
Hospira, Inc.: 322 products in the FDA NDC directory, labeler code 0409
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hospira, Inc. (labeler code 0409) lists 322 products in the FDA National Drug Code Directory, covering 100 finished drugs by generic name. By type: 321 prescription drugs, 1 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 17, 2026.
The request: Watch Hospira, Inc. (FDA labeler code 0409): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0409
- Products in commercial distribution
- 322
- Packages
- 395
- Finished drugs by generic name
- 100
- Prescription products
- 321
- Over the counter products
- 0
- Controlled substance products
- Schedule II 21, Schedule III 5, Schedule IV 12
- Flagged as original packager
- 279 of 279 products that carry the flag
- Started marketing in the last 12 months
- 7
- Products with a marketing end date set
- 8
- Earliest marketing start
- September 13, 1985
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 183 | 56.8% |
| New drug applications (NDA) | 138 | 42.9% |
| Drugs for further processing | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 321 | 99.7% |
| Drugs for further processing | 1 | 0.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 228 | 70.8% |
| Injection, solution, concentrate | 31 | 9.6% |
| Injection, powder, lyophilized, for solution | 30 | 9.3% |
| Injection, powder, for solution | 22 | 6.8% |
| Injection, emulsion | 7 | 2.2% |
| Solution | 2 | 0.6% |
| Injection | 2 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Propofol | 0409-1511 | Injection, emulsion | Generic drugs (ANDA) | August 17, 2026 |
| Propofol | 0409-0501 | Injection, emulsion | Generic drugs (ANDA) | August 17, 2026 |
| Propofol | 0409-0010 | Injection, emulsion | Generic drugs (ANDA) | August 17, 2026 |
| Dobutamine in Dextrose | 0409-1100 | Injection, solution | New drug applications (NDA) | March 16, 2026 |
| Dobutamine in Dextrose | 0409-0151 | Injection, solution | New drug applications (NDA) | March 16, 2026 |
| Dobutamine in Dextrose | 0409-0025 | Injection, solution | New drug applications (NDA) | March 16, 2026 |
| Ondansetron | 0409-2271 | Injection, solution | Generic drugs (ANDA) | December 1, 2025 |
| Dopamine Hydrochloride in Dextrose | 0409-1858 | Injection, solution | New drug applications (NDA) | November 3, 2025 |
| Dopamine Hydrochloride in Dextrose | 0409-0042 | Injection, solution | New drug applications (NDA) | November 3, 2025 |
| Potassium Phosphates | 0409-0032 | Injection, solution, concentrate | Generic drugs (ANDA) | September 29, 2025 |
| Marcaine | 0409-2510 | Injection, solution | New drug applications (NDA) | August 28, 2025 |
| Marcaine | 0409-1530 | Injection, solution | New drug applications (NDA) | August 25, 2025 |
| Marcaine | 0409-7535 | Injection, solution | New drug applications (NDA) | May 27, 2025 |
| Morphine sulfate | 0409-2022 | Injection, solution | New drug applications (NDA) | April 21, 2025 |
| Marcaine | 0409-2253 | Injection, solution | New drug applications (NDA) | April 14, 2025 |
| Sterile Water | 0409-0024 | Injection | New drug applications (NDA) | March 31, 2025 |
| Precedex | 0409-7875 | Injection, solution | New drug applications (NDA) | March 24, 2025 |
| Precedex | 0409-7853 | Injection, solution | New drug applications (NDA) | March 24, 2025 |
| Precedex | 0409-7838 | Injection, solution | New drug applications (NDA) | March 24, 2025 |
| Marcaine | 0409-5010 | Injection, solution | New drug applications (NDA) | February 3, 2025 |
| Midazolam | 0409-0001 | Injection, solution | Generic drugs (ANDA) | January 27, 2025 |
| Fluconazole | 0409-4321 | Injection, solution | Generic drugs (ANDA) | January 6, 2025 |
| Fluconazole | 0409-3435 | Injection, solution | Generic drugs (ANDA) | January 6, 2025 |
| Ondansetron | 0409-0009 | Injection, solution | Generic drugs (ANDA) | December 16, 2024 |
| Marcaine | 0409-0525 | Injection, solution | New drug applications (NDA) | December 9, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.